Hepatitis C in state correctional facilities

Preventive Medicine

Volumn 28, Issue 1, 1999, Pages 92-100

  Spaulding, Anne ^a,b   Greene, Carolyn ^c   Davidson, Kerith ^c   Schneidermann, Michelle ^c   Rich, Josiah ^d  

^a RHODE ISLAND HOSPITAL   (United States)

^b RHODE ISLAND DEPARTMENT OF CORRECTIONS   (United States)

^c BROWN UNIVERSITY   (United States)

^d MIRIAM HOSPITAL   (United States)

Author keywords

Cost analysis; Hepatitis C; Prisons; Review

Indexed keywords

INTERFERON;

ARTICLE; FEMALE; HEALTH CARE COST; HEALTH SURVEY; HEPATITIS C; HUMAN; MALE; MODEL; PRIORITY JOURNAL; PRISON; SCREENING; SEROPREVALENCE; UNITED STATES;

EID: 0032790517     PISSN: 00917435     EISSN: None     Source Type: Journal    
DOI: 10.1006/pmed.1998.0418     Document Type: Article

References (31)

1. Choo Q-L, Kuo G, Weiner A J, Overby L R, Bradley D W, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 244:1989;359-362.
2. Hepatology. 26:1997;2S-10S.
3. Alter, M, J, Epidemiology of hepatitis C, 1997 Mar 24, 6, 67, 70.
4. Conry-Cantilena C, VanRaden M A, Gibble J, Melpolder J, Shakil A O, Viladomiu L. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med. 334:1996;1691-1696.
5. Ruiz, J, D, Mikanda, J, Seroprevalence of HIV, hepatitis B, hepatitis C, and risk behaviors among inmates entering the California correctional system, Sacramento, California, Department of Health Services, 1996 Mar.
6. Alter M J. The detection, transmission, and outcome of hepatitis C virus infection. Infect Agents Dis. 2:1993;155-166.
7. Brown B S, Beschner G M. Handbook on risk of AIDS: injection drug users and sexual partners. 1993;Greenwood Press, Westport. p. 338.
8. Alter M J, Margolis H S, Krawczynski K. The natural history of community-acquired hepatitis C in the United States. N Engl J Med. 327:1992;1899-1905.
9. Seeff L B, Buskell-Bales Z, Wright E C. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med. 327:1992;1906-1911.
10. Koretz R L, Abbey H, Coleman E, Gitnick G. Non-A, non-B post-transfusion hepatitis: looking back in the second decade. Ann Intern Med. 119:1993;110-115.
11. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S. Randomized trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic acute hepatitis C with cirrhosis. Lancet. 346:1995;1051-1055.
12. Hoofnagle J H, Mullen K D, Jones D B. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. N Engl J Med. 315:1986;1575-1578.
13. Carithers, R, L, Jr, Therapy of hepatitis C: interferon alpha-2b, 1997 Mar 24, 6, 83, 5.
14. Reichard O, Glaumann H, Fryden A, Norkrans G, Schvarcz R, Sonnerborg A. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alpha-2b treatment. Hepatology. 21:1995;918-922.
15. Saracco G, Rosina F, Abate M L, Chiandussi L, Gallo V, Cerutti E. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-α2b. Hepatology. 18:1993;1300-1305.
16. Davis G L, Balart L A, Schiff E R, Lindsay K, Bodenheimer H C Jr, Perrillo R P. Treatment of chronic hepatitis C with recombinant interferon alpha: a multicenter randomised, controlled trial. N Engl J Med. 321:1989;1501-1506.
17. Saracco G, Rosino F, Torrani-Crenzia M R, Lattore V, Chiandussi L, Gallo V. A randomized, controlled trial of interferon alpha-2b as therapy for chronic non-A, non-B hepatitis. J Hepatol. 11:1990;543-549.
18. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D. Comparison of 1 or 3 MU of interferon alpha-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology. 101:1991;497-502.
19. Cromie S L, Jenkins P J, Bowden D S, Dudley F J. Chronic hepatitis C: effect of alcohol on hepatic activity and viral titre. J Hepatol. 25:1996;821-826.
20. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 349:1997;825-832.
21. Shahara A I, Hunt C M, Hamilton J D. Hepatitis C. Ann Intern Med. 125:1996;658-668.
22. Iwarson S, Norkrans G, Wesjstål R. Hepatitis C: natural history of a unique infection. Clin Infect Dis. 20:1995;1361-1370.
23. Farci P, Alter H J, Govindarajan S, Wong D C, Engle R, Lesniewski R R. Lack of protective immunity against reinfection with hepatitis C virus. Science. 258:1992;135-140.
24. Camp, C, G, Camp, G, M, The corrections yearbook 1996, South Salem, NY, Criminal Justice Institute, 1996.
25. Anno B J, Faiver K L, Harness J K. A preliminary model for determining limits for correctional health care services. J Correct Health Care. 3:1996;67-84.
26. Dusheiko G M, Roberts J A. Treatment of chronic type B and C hepatitis with interferon alpha: an economic appraisal. Hepatology. 1995;1863-1871.
27. Shiell A, Briggs A, Farrell G C. The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C. Med J Aust. 1994;268-272.
28. Bennett W G, Pauker S G, Davis G L, Wong J B. Modeling therapeutic benefit in the midst of uncertainty: therapy for hepatitis C. Dig Dis Sci. 4:1996;56S-62S.
29. Koff, R, S, Cost-effectiveness analysis, 1997 Mar 24, 6, 137, 9.
30. Skolnick A. Look behind bars for key to control STDs. JAMA. 279:1998;97-98.
31. Butler T G, Dolan K A, Ferson M J, McGuinness L M, Brown P R, Robertson P W. Hepatitis B and C in New South Wales prisons: prevalence and risk factors. Med J Aust. 166:1997;127-130.